Manufacturing and quality control of cell-based tumor vaccines: A scientific and a regulatory perspective

被引:18
|
作者
Hinz, Thomas
Buchholz, Christian J.
van der Stappen, Ton
Cichutek, Klaus
Kalinke, Ulrich
机构
[1] Paul Ehrlich Inst, Div Immunol, D-63225 Langen, Germany
[2] Paul Ehrlich Inst, Div Med Biotechnol, D-63225 Langen, Germany
[3] Natl Inst Publ Hlth & Environm, Ctr Biol Med & Med Technol, NL-3720 BA Bilthoven, Netherlands
关键词
cancer vaccine; potency; regulatory guidance document;
D O I
10.1097/01.cji.0000211305.98244.56
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tumor vaccines play an increasingly important role in the therapy of various malignant diseases. The efficacy of these new products is currently being explored in many clinical trials all over the world. Cell-based tumor vaccines can be classified as somatic cell therapy, or, depending on whether genetic modifications have been applied, as gene-transfer medicinal products. Few specific guidance documents are available to standardize the development and production of cell-based tumor vaccines. Here, we review the different types of cell-based cancer vaccines that are currently being used in clinical trials. Furthermore, we discuss regulatory guidance documents available in the European Union and describe methods that have been applied so far to ensure that the cell-based vaccines meet acceptable standards, including potency assays.
引用
收藏
页码:472 / 476
页数:5
相关论文
共 50 条
  • [1] Overview of tumor cell-based vaccines
    Copier, John
    Dalgleish, Angus
    [J]. INTERNATIONAL REVIEWS OF IMMUNOLOGY, 2006, 25 (5-6) : 297 - 319
  • [2] Immunotherapy of cancer with dendritic cell-based tumor vaccines
    Gilboa, E
    Nair, SK
    Boczkowski, D
    Mitchel, D
    Faiola, B
    [J]. CANCER GENE THERAPY, 1997, 4 (05) : 314 - 314
  • [3] Immunotherapy of cancer with dendritic cell-based tumor vaccines
    Gilboa, E
    Nair, SK
    Morse, M
    Boczkowski, D
    Deng, Y
    Lyerly, HK
    [J]. ANNALS OF ONCOLOGY, 1998, 9 : 7 - 7
  • [4] Pathogen inactivation of tumor cell preparations for dendritic cell-based vaccines
    Fung, MK
    Whiteside, TL
    [J]. TRANSFUSION, 2003, 43 (09) : 88A - 88A
  • [5] Liposomes as cytokine-supplement in tumor cell-based vaccines
    van Slooten, ML
    Kircheis, R
    Koppenhagen, FJ
    Wagner, E
    Storm, G
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1999, 183 (01) : 33 - 36
  • [6] Dendritic-Tumor Fusion Cell-Based Cancer Vaccines
    Koido, Shigeo
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (06):
  • [7] Comparative evaluation of techniques for the manufacturing of dendritic cell-based cancer vaccines
    Dohnal, Alexander Michael
    Graffi, Sebastian
    Witt, Volker
    Eichstill, Christina
    Wagner, Dagmar
    Ul-Haq, Sidrah
    Wimmer, Doris
    Felzmann, Thomas
    [J]. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2009, 13 (01) : 125 - 135
  • [8] Comparative evaluation of techniques for the manufacturing of dendritic cell-based cancer vaccines
    Ul-Haq, S.
    Dohnal, A. M.
    Volker, W.
    Leithner, B.
    Gruber, P.
    Felzmann, T.
    [J]. WIENER KLINISCHE WOCHENSCHRIFT, 2008, 120 : 116 - 116
  • [9] Current status of autologous breast tumor cell-based vaccines
    Kurtz, Samantha L.
    Ravindranathan, Sruthi
    Zaharoff, David A.
    [J]. EXPERT REVIEW OF VACCINES, 2014, 13 (12) : 1439 - 1445
  • [10] Dendritic cell-based tumor vaccines and antigen presentation attenuators
    Evel-Kabler, Kevin
    Chen, Si-Yi
    [J]. MOLECULAR THERAPY, 2006, 13 (05) : 850 - 858